SAGE Therapeutics Inc
NASDAQ:SAGE

Watchlist Manager
SAGE Therapeutics Inc Logo
SAGE Therapeutics Inc
NASDAQ:SAGE
Watchlist
Price: 9.25 USD 0.33% Market Closed
Market Cap: 579.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

SAGE Price Targets Summary
SAGE Therapeutics Inc

Wall Street analysts forecast SAGE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SAGE is 8.82 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

SAGE Lowest Forecast
Wall Street Target
5.05 USD
45% Downside
SAGE Average Forecast
Wall Street Target
8.82 USD
5% Downside
SAGE Highest Forecast
Wall Street Target
12.6 USD
36% Upside
Lowest
Price Target
5.05 USD
45% Downside
Average
Price Target
8.82 USD
5% Downside
Highest
Price Target
12.6 USD
36% Upside
SAGE Therapeutics Inc Competitors:
Price Targets
GNS
Genus PLC
29% Upside
STOK
Stoke Therapeutics Inc
93% Upside
EXEL
Exelixis Inc
3% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
30% Upside
GNS
Genus PLC
29% Upside
STOK
Stoke Therapeutics Inc
93% Upside
EXEL
Exelixis Inc
3% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
30% Upside
BRNS
Barinthus Biotherapeutics PLC
415% Upside
OSE
OSE Immunotherapeutics SA
234% Upside
H
145020
Hugel Inc
15% Upside
HPHA
Heidelberg Pharma AG
223% Upside

Revenue
Forecast

Revenue Estimate
SAGE Therapeutics Inc

The compound annual growth rate of SAGE Therapeutics Inc's revenue for the next 3 years is 56%.

N/A
Past Growth
56%
Estimated Growth
Estimates Accuracy
11%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SAGE Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SAGE Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
What are analyst estimates?

See Also

Summary
SAGE intrinsic value, competitors valuation, and company profile.
DCF Valuation
SAGE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SAGE stock valuation using valuation multiples.
Wall Street Estimates
SAGE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SAGE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SAGE's stock price target?
Price Target
8.82 USD

According to Wall Street analysts, the average 1-year price target for SAGE is 8.82 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

What is SAGE Therapeutics Inc's Revenue forecast?
Projected CAGR
56%

The compound annual growth rate of SAGE Therapeutics Inc's revenue for the next 3 years is 56%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.